A Randomised phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advaneced or recurrent gastric cancer resistant to S-1 - Trial group of Irinotecan based Chemotherapy for S-1 failed Stomach Cancer (TRICS)

ECRI0 个研究点目标入组 200 人开始时间: 2009年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Blood transfusion, blood products, or hematopoietic factor products, such as G-CSF, within 14 days before enrollment of this study. (2) Present and/or drug hypersensitivity or severe drug allergy. (3) Active double cancer. (4) With uncontrolled pleural effusion or ascites. (5) With pericardial effusion. (6) With infectious disease which needs treatment. (7) With symptomatic brain metastasis. (8) With marked ECG abnormalities. (9) With serve heart diseases, such as congestive heart failure, symptomatic coronary artery disease, inadequately controlled arrhythmia, myocardial infarction during the previous 12 months, etc. (10) With severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe pulmonary emphysema, etc.). (11) With fresh gastrointestinal hemorrhage. (12) Watery stool (diarrhea). (13) Intestinal paralysis or ileus. (14) With a history of central nervous system disorder. (15) With senile dementia. (16) With psycologic disorder which disturbs recruiting to the study (17) Uncontrolled diabetes mellitus. (18) Receiving atazanavir sulfate. (19) Pregnant and/or nursing women. (20) Inappropriate recruit to the study judged by an investigator in charge.

发起方